Both sets of data revealed that HIF1A was significantly upregulated in high-grade glioma (HGG, including WHO grade III and grade IV, referred to as GBM) compared with low-grade glioma (LGG, including WHO grade I and II) (Supplemental Figure 3, A and B). This evidence concerns the gene HIF1A and central nervous system cancer.